Fluicell held annual general meeting 2026
The board was expanded with new members and incentive programs were approved.
See the latest news and media coverage for Fluicell. We track all announcements, press releases, and industry mentions in real time, all in one place.
Tissue engineering platform for regenerative medicine
fluicell.comLast updated
In short: Fluicell achieved profitability and record revenue growth in early 2026, bolstered by strategic partnerships and expansion of its patent portfolio.
The board was expanded with new members and incentive programs were approved.
Net sales increase to 6.1 MSEK, 26 times higher than the previous year. EBITDA becomes positive at 3.4 MSEK. Patent granted in the EU.
Karin Jennbacken is Executive Director at AstraZeneca with expertise in cardiovascular research and regenerative medicine. The proposal complements the board election to the annual general meeting 2026.
Niklas Frisk is elected as chairman and Alex Scheepers, Kader Abdul, Peter Kjäll as new board members. Re-election of Owe Orwar, Daniel Chiu and Carl Fhager.
Fluicell reports an operating result of 3.3 million kronor (-2.6) in the first quarter of 2026. Sales increased to 6.1 million kronor (0.2) with revenues of 8.4...
The medical technology company Fluicell reports an operating result of -0.1 million kronor (-1.8) for the fourth quarter of 2025.
Fluicell AB Annual cash flow by MarketWatch. View FLUI net cash flow, operating cash flow, operating expenses and cash dividends.
The method that has been patented involves creating biological structures on surfaces via a multi-step process, and is an important part of the company's Nexocyte platform, which...
Track Fluicell and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.